In vitro: The combined use of glycolysis inhibitor WP1122 and HDAC inhibitors (such as sodium butyrate and sodium valproate) demonstrated significant synergistic anti-cancer effects, inhibiting the proliferation of GBM cells and inducing apoptosis.In vivo: In mouse models, the combination therapy significantly inhibited tumor growth, improved the survival rate of the mice, and no obvious toxicity was observed (70). This evidence concerns the gene HDAC9 and cancer.